InfuSystem (INFU) The Sidoti Small-Cap Virtual Investor Conference summary

Business Overview and Core Competencies

• Operates as a healthcare services company with over 38 years of experience and a fleet of more than 100,000 devices in service, serving 18 of the top 20 U.S. hospitals and over 2,450 care sites.

• Maintains over 800 payer contracts, covering more than 96% of the U.S. population and enabling broad insurance billing.

• Core strengths include logistics, biomedical capabilities, clinical expertise, and revenue cycle management, adaptable to various medical devices.

• Employs more than 500 staff across seven major service areas in the U.S. and Canada, offering device-agnostic services and 24/7 patient support.

• Operates ISO 9001/13485 certified facilities and employs over 200 biomedical technicians.

Oncology Business and Growth

• Holds about two-thirds of the chemotherapy infusion market, with stable, slow growth in low single digits annually.

• Revenue cycle improvements have boosted total growth to around 8% in the past year.

• Oncology business expected to grow at low to mid-single digits moving forward.

• Devices are capitalized over seven years, often lasting 10–12 years, and are reusable.

• Patient Services contributed $76.5M (61%) and Device Solutions $49.3M (39%) to 2023 revenue.

Strategic Initiatives, Partnerships, and New Business Lines

• Expanded into new therapies and partnerships, leveraging oncology expertise for growth.

• Recent agreements include national distribution with Genadyne, Smith+Nephew, and ChemoMouthpiece.

• GE partnership fully implemented, generating $10–$12 million in revenue, with ongoing operational efficiency improvements.

• Acquired and integrated two biomedical services companies in 2021 to enhance Device Solutions.

• Signed agreement with Solo-Dex for proprietary nerve block catheters.